TABLE 2.

Summary of clinical trials in North America (excludes trials that only study donation)

Sponsor	Control	Participants	Population
Hackensack Meridian Health	None (single arm)	55	Two tracks: ‐Hospitalized, without mechanical ventilation ‐Hospitalized, with mechanical ventilation
Primary outcomes: ‐First track: mechanical ventilation rate at 7 days from starting treatment ‐Second track: mortality at 30 days
Hamilton Health Sciences Corporation	Standard of care	1200	Hospitalized, nonintubated patients
Primary outcomes: Intubation or death in the hospital at 30 days
Stony Brook University	Standard plasma	500	Hospitalized patients (intubation status unspecified)
Primary outcomes: Ventilator‐free days through Day 28 postrandomization (patients who die in this period are assigned 0 days)
University of Chicago	None (single arm)	10	Severe or immediately life‐threatening disease
Primary outcomes: ‐Number of consented donors, amount of plasma successfully harvested ‐Number of patients transfused ‐Level of respiratory support (e.g., room air, high flow oxygen, intubation) at 28 days after plasma administration
Johns Hopkins University	Standard plasma	150	Asymptomatic, with negative PCR test and high risk exposure and higher risk for severe illness
Primary outcomes: ‐Death ‐Requiring mechanical ventilation and/or in ICU ‐Non‐ICU hospitalization, requiring supplemental oxygen ‐Non‐ICU hospitalization, not requiring supplemental oxygen ‐Not hospitalized, but with clinical and laboratory evidence of COVID‐19 infection ‐Not hospitalized, no clinical evidence of COVID‐19 infection, but positive PCR for SARS‐CoV‐2
Baylor Research Institute	Standard of care	115	Hospitalized patients (intubation status unspecified)
Primary outcome: Reduction in ventilation and oxygen support